Implantable drug delivery systems (IDDS) after failure of comprehensive medical management (CMM) can palliate symptoms in the most refractory cancer pain patients

Journal of Palliative Medicine

Volumn 8, Issue 4, 2005, Pages 736-742

  Smith, Thomas J ^a   Coyne, Patrick J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOCAL ANESTHETIC AGENT; OPIATE;

ADULT; AGED; ARTICLE; CANCER PAIN; CANCER SURVIVAL; CLINICAL TRIAL; COMPREHENSIVE MEDICAL MANAGEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROSSOVER PROCEDURE; DRUG EFFICACY; EXPERT SYSTEM; FEMALE; HUMAN; IMPLANTABLE PORT SYSTEM; INFUSION SYSTEM; MAJOR CLINICAL STUDY; MALE; PALLIATIVE THERAPY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT FAILURE; VISUAL ANALOG SCALE;

AGED; COHORT STUDIES; FEMALE; HUMANS; INFUSION PUMPS, IMPLANTABLE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASMS; PAIN, INTRACTABLE; PALLIATIVE CARE; PROSPECTIVE STUDIES;

EID: 24644515413     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2005.8.736     Document Type: Article

References (11)

1. Smith TJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz-Marx RL, Buscher E, Catala E, Bryce DA, Coyne PJ, Pool GE; Implantable Drug Delivery System Study Group: Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: Impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002;20:4040-4049.
2. Smith TJ, Coyne PJ, Staats PS: What is the evidence for implantable drug delivery systems for refractory pain. Support Cancer Ther 2004;1:1-5.
3. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS: When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995;61:277-284.
4. Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KL, Grond S: Symptoms during cancer pain treatment following WHO-guidelines: A longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 2001;93:247-257.
5. DuPen S, DuPen A, Polossar N, Hapsberry J, Kraybill BM, Stillman M, Panke J, Everly R, Syrjala K: Implementing guidelines for cancer pain management: Results of a randomized controlled clinical trial. J Clin Oncol 1999;17:361-370.
6. Bedder MD, Burchiel K, Laron A. Cost analysis of two implantable narcotic delivery system. J Pain Symptom Manage 1991;6:368-373.
7. Hillner BE, Smith TJ, Coyne PJ, Cassel B: The Implantable Drug Delivery Trial Group preliminary estimates of the cost effectiveness (CE) ratio of implantable drug delivery systems (IDDS) compared to comprehensive medical management (CMM) in patients with refractory cancer pain. Proc Am Soc Clin Oncol 2003.
8. Earle CC, Chapman R, Baker C, Bell CM, Stone PW, Sandberg EA, Neumann PJ: Systematic Overview of Cost-Utility Assessments in Oncology. J Clin Oncol 2000;18:3302-3317.
9. Grunberg SM, Hesketh PJ: Control of chemotherapy-induced emesis. N Engl J Med 1993;329:1790-1796.
10. Hillner BE, Weeks JC, Desch CE, Smith TJ: Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2000; 18:72-79.
11. Jacox A, Carr D, Payne R, et al: Management of cancer pain. Clinical practice guideline no. 9. Rockville, MD: Agency for Health Care Policy and Research, 1994 (AHCPR publication no 94-0592). AHCPR Publication 1994;94-0592: